At July 31, 2016, the $8.8 million received was included in "Other current liabilities" in the accompanying consolidated balance sheet pending the issuance of the member interests.

Rafael Pharmaceuticals, Inc. [Member] | Convertible promissory note [Member] | Howard and Deborah Jonas [Member]

Investment in Rafael Pharmaceuticals, Inc. (Textual)

Series C convertible notes

$ 525

Rafael Pharmaceuticals, Inc. [Member] | Convertible promissory note [Member] | The Howard S. and Deborah Jonas Foundation [Member]

Investment in Rafael Pharmaceuticals, Inc. (Textual)

Series C convertible notes

525

CS Pharma Holdings, LLC [Member]

Investment in Rafael Pharmaceuticals, Inc. (Textual)

Maximum amount of investment

10,000

Noncontrolling interests

$ 7,200

Holds percentages of interest

50.00%

Additional paid-in capital

$ 2,800

CS Pharma Holdings, LLC [Member] | Convertible promissory note ("Series D Note") [Member]

Investment in Rafael Pharmaceuticals, Inc. (Textual)

Convertible promissory note, principal amount

$ 10,000

Convertible promissory note, rate of interest

3.50%

Convertible promissory note, maturity date

Sep. 16, 2018

Additional amount of investment funded

$ 8,000

Purchase shares of capital stock percentage

56.00%

Exercise warrants value

$ 10,000

Initial amount of investment amounts paid

$ 5,000

Convertible notes conversion features, description

The Series D Note also includes a mandatory conversion into Rafael common stock upon a qualified initial public offering, and conversion at the holder's option upon an unqualified financing event. In all cases, the Series D Note conversion price is based on the applicable financing purchase price.

Warrants expiry date

Dec. 31, 2020

Warrant, description

The exercise price of the warrant is the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments. The minimum initial and subsequent exercises of the warrant shall be for such number of shares that will result in at least $5 million of gross proceeds to Rafael, or such lesser amount as represents 5% of the outstanding capital stock of Rafael, or such lesser amount as may then remain unexercised. The warrant will expire upon the earlier of December 31, 2020 or a qualified initial public offering or liquidation event.

IDT-Rafael Holdings, LLC [Member]

Investment in Rafael Pharmaceuticals, Inc. (Textual)

Contractual right to receive additional shares, description

(i) Food and Drug Administration approval of a Rafael drug application, (ii) an initial public offering of Rafael at a valuation of over $500 million, or (iii) a sale of Rafael above certain valuations. Currently, none of the conditions have been satisfied and the right remains contingent. On September 14, 2017, IDT-Rafael Holdings distributed this right to its members on a pro rata basis such that the Company received the right to 9% of the outstanding capital stock of Rafael and Mr. Jonas received the right to 1% of the outstanding capital stock of Rafael. In addition, as compensation for assuming the role of Chairman of the Board of Rafael, and to create additional incentive to contribute to the success of Rafael, on September 19, 2017, the Company transferred its right to receive 9% of the outstanding capital stock of Rafael to Mr. Jonas. The right is further transferable at the discretion of Mr. Jonas.

IDT-Rafael Holdings, LLC [Member] | Subsequent Event [Member]

Investment in Rafael Pharmaceuticals, Inc. (Textual)

Percentage of contractual right to receive additional shares

10.00%

IDT-Rafael Holdings, LLC [Member] | IDT Corporation [Member] | Subsequent Event [Member]

Investment in Rafael Pharmaceuticals, Inc. (Textual)

Percentage of contractual right to receive additional shares

9.00%

IDT-Rafael Holdings, LLC [Member] | Howard S. Jonas [Member] | Subsequent Event [Member]

Investment in Rafael Pharmaceuticals, Inc. (Textual)

Percentage of contractual right to receive additional shares

1.00%